and treatment, if sensitivity is lower than conventional testing then there is potentially increased transmission from false-negative patients. The net effect depends upon characteristics of the particular PoCT.

Conclusion PoCT sensitivity and specificity are key determinants of whether replacing conventional testing is likely to reduce or increase the incidence of infection. Importantly, if the convenience of PoCT increases testing rates then diagnoses might initially increase even though incidence falls; interpretation of surveillance data needs to account for this. This work is the foundation of a user-friendly web-based tool assessing the (cost-) effectiveness of introducing PoCTs in different local settings.

Disclosure of interest statement CED, ESS, NG, EHE, RHJ, YC, CML, and PJW thank Innovate UK for funding. PJW thanks the UK Medical Research Council for Centre funding (grant MR/K010174/1), and also thanks the UK National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Modelling Methodology at Imperial College London in partnership with Public Health England (PHE) for funding (grant HPRU-2012-10080). The funding sources had no involvement in the study design or conduct; the collection, analysis and interpretation of data; the preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, or Public Health England. CED was employed for part of the project by the National Chlamydia Screening Programme. The other authors declare no competing interests.

P09.14 IMPLEMENTATION OF ORAL AND SELF-COLLECTED RECTAL SWABS FOR *N. GONORRHOEAE* AND *C. TRACHOMATIS* DETECTION AS A COMPONENT OF LOCAL HEALTH DEPARTMENT OUTREACH TESTING

¹BC Barr, ²J Nall, ^{1,2}CJ McNeil, ¹LH Bachmann*. ¹Wake Forest University Health Sciences, Winston-Salem, NC, USA; ²Forsyth County Department of Public Health, Winston-Salem, NC, USA

10.1136/sextrans-2015-052270.398

Introduction The availability of extra-genital nucleic acid amplification testing (NAAT) for gonorrhoea (GC) and chlamydia (CT) is limited in many clinical and outreach settings. A recent initiative in Forsyth County, NC funded NAAT testing at oropharyngeal and rectal sites in both of these settings.

Methods A retrospective chart review was conducted for all males and females aged 12–80 who reported to an outreach site or STD clinic (MSM only) January 1, 2014 to February 28, 2015.

Results Clinic: 131 rectal, 163 pharyngeal, and 176 urethral NAAT tests were performed on 181 males. Twenty-five rectal (19.1%), 22 pharyngeal (13.5%), and 22 (12.5%) urethral specimens were GC positive. 24 rectal (18.3%) and 7 urethral (4.0%) were CT positive. 5 rectal GC (20.0%), 8 pharyngeal GC (36.4%), and 13 rectal CT (54.2%) infections would have been missed in the absence of extra-genital testing.

Outreach 47 rectal, 157 pharyngeal, and 162 urogenital NAATs were collected. For GC, 3 rectal (6.4%), 3 pharyngeal (1.9%), and 2 urogenital (1.2%) specimens were positive. Six (12.8%) and 9 (5.6%) individuals were positive for rectal and urogenital CT, respectively. 2 rectal GC (66.7%), 3 pharyngeal GC (100%), and 4 rectal CT (66.7%) infections would have been missed without extra-genital NAAT.

When NAAT and bacterial culture for GC were run on the same samples from clinic patients, culture detected 48% (12/25) of the rectal and 45.2% (10/22) of the pharyngeal infections detected by NAAT.

Conclusion A significant prevalence of extra-genital GC and CT infections were noted in both the clinic and outreach populations. In the absence of NAAT-based extra-genital testing approximately half of rectal and pharyngeal GC infections would have been missed with culture and more than half of the rectal CT infections would have been missed. Assurance of access of NAAT-based extra-genital testing is critical for STI control efforts.

P09.15 TIME TO CLEARANCE FOR MOLECULAR TEST-OF-CURE AMONG MEN TREATED FOR URETHRAL, PHARYNGEAL, OR RECTAL GONORRHOEA IN SAN FRANCISCO, 2013–2014

TQ Nguyen*, SE Cohen, T Noohi, RP Kohn, SS Philip. *San Francisco Department of Public Health*

10.1136/sextrans-2015-052270.399

Introduction Due to the potential emergence of cephalosporin-resistant *Neisseria gonorrhoeae* (NG), some public health agencies recommend a test of cure (TOC) using nucleic acid amplification tests (NAATs). NAATs can remain positive after the infection has been effectively eradicated; the optimal time to obtain a TOC is unclear. To inform TOC recommendations, we conducted NAATs for 21 days following treatment for men who have sex with men (MSM) NG-infected at the urethra, rectum or pharynx.

Methods MSM with untreated urethral, rectal or pharyngeal gonorrhoea were eligible. At enrollment, prior to provision of antibiotics, infection-site specimens were collected by a clinician for culture and NAAT testing. Participants whose enrollment-day specimens were negative were excluded. Participants self-collected daily infection-site specimens (rectal or pharyngeal swabs or urine) for 3 weeks and returned on days 7, 14, and 21 to submit their self-collected specimens for NAAT testing and provide clinician-collected specimens for culture and NAAT testing. We planned to follow at least 10 participants for at least 7 days in each of the urethral (U), rectal (R), and pharyngeal (P) study arms.

Results We enrolled 46 MSM. Eleven participants had negative enrollment-day specimens, and 4 did not return after enrollment. Of the 31 included in the analysis (11U, 11R, 9P), 22 (71%) provided all 21 days of specimens; another 6 provided nearly all study specimens. The majority (94%) were negative on Day 7 (11U, 11R, 7P), though 4 (2U, 1R, 1P) had subsequent positive results.

Conclusion A high proportion of participants had a negative NAAT before antibiotics, despite a prior positive result, indicating either an original false positive result or natural clearance of infection. Additional analyses will determine the effectiveness of other TOC time-points, including median time to: first negative result, 3 consecutive negative results, and clearance (consistently negative results through follow-up); and clearance at Days 14 and 21.

Disclosure of interest statement No pharmaceutical grants were received in the development of this study.